Last updated: August 23, 2026
XIPERE is a niche ophthalmic corticosteroid launched by Bausch + Lomb for macular edema associated with uveitis. Its commercial proposition is based on suprachoroidal delivery of triamcinolone acetonide, rather than the intravitreal delivery used by major competing steroid products. Public filings do not disclose standalone XIPERE sales, making exact market share, revenue growth and profitability impossible to verify. The product remains commercially relevant but is unlikely to become a major revenue contributor to Bausch + Lomb without broader physician adoption, stronger reimbursement and expansion into additional retinal indications.
What is XIPERE and what market does it address?
XIPERE is triamcinolone acetonide injectable suspension, 40 mg/mL, administered into the suprachoroidal space using the proprietary SCS Microinjector. The FDA approved it in October 2021 for the treatment of macular edema associated with uveitis in adults.[1]
The labeled dose is 4 mg, delivered as 0.1 mL. Repeat treatment may be considered after at least 12 weeks, subject to clinical judgment.[1]
Uveitis is an inflammatory eye disease that can cause macular edema and vision loss. The addressable market is narrower than the markets for diabetic macular edema, age-related macular degeneration or retinal vein occlusion. The commercial opportunity is concentrated among:
- Retina specialists
- Uveitis specialists
- Ophthalmology practices treating posterior-segment inflammation
- Patients who respond inadequately to systemic therapy, local corticosteroids or anti-VEGF treatment
- Patients for whom an intravitreal implant or injection is undesirable
XIPERE’s main product-level differentiation is the delivery route. Suprachoroidal administration is intended to place corticosteroid closer to the choroid and retina while limiting exposure to the anterior chamber and vitreous relative to conventional intravitreal delivery.
How does XIPERE compare with competing uveitis treatments?
XIPERE competes with approved ocular corticosteroids, off-label triamcinolone, systemic immunosuppression and biologic or anti-VEGF therapies used in selected cases.
| Product |
Active ingredient |
Delivery |
Principal uveitis relevance |
Commercial position |
| XIPERE |
Triamcinolone acetonide |
Suprachoroidal injection |
Macular edema associated with uveitis |
Newer, procedure-based product |
| Ozurdex |
Dexamethasone |
Intravitreal biodegradable implant |
Noninfectious uveitis affecting the posterior segment; retinal vein occlusion-related edema |
Established branded steroid |
| Retisert |
Fluocinolone acetonide |
Surgically implanted intravitreal device |
Chronic noninfectious posterior uveitis |
Long-duration treatment, invasive procedure |
| YUTIQ |
Fluocinolone acetonide |
Intravitreal implant |
Chronic noninfectious posterior uveitis |
Long-duration steroid alternative |
| Intravitreal triamcinolone |
Triamcinolone acetonide |
Intravitreal injection |
Off-label inflammatory retinal disease |
Low-cost substitute |
| Systemic corticosteroids and immunosuppressants |
Various |
Oral or injectable |
Uveitis control and systemic disease |
Important where ocular disease is part of a broader inflammatory condition |
Ozurdex has a broader established retinal franchise and greater physician familiarity. YUTIQ and Retisert offer prolonged corticosteroid exposure, which can reduce treatment frequency. Generic or compounded intravitreal triamcinolone creates a significant price constraint.
XIPERE can compete most effectively where physicians value a targeted suprachoroidal approach, seek to avoid an intravitreal implant, or need treatment specifically for uveitic macular edema.
What is XIPERE’s FDA regulatory status?
The FDA approved XIPERE under New Drug Application 214659 on October 22, 2021.[1] It was the first FDA-approved product using suprachoroidal delivery for this indication.
The product does not have biologic status and is not eligible for the biosimilar pathway. A future competitor would generally pursue an abbreviated or full small-molecule pathway depending on the relevant formulation, device and clinical requirements.
The key regulatory limitations are the narrow labeled indication and the absence of an approved indication in larger retinal markets such as diabetic macular edema or neovascular age-related macular degeneration. Expansion into those markets would require additional clinical evidence and regulatory approval.
What are the principal safety and adoption issues?
The label identifies risks associated with corticosteroid ocular therapy, including increased intraocular pressure, glaucoma, cataract formation, endophthalmitis and retinal or choroidal complications.[1]
Suprachoroidal injection also requires specialized training and equipment. A practice must acquire or use the SCS Microinjector and integrate a less familiar injection technique into its workflow. That creates an adoption barrier compared with familiar intravitreal injections.
What is the market size for XIPERE?
No authoritative public source discloses a standalone XIPERE market size. The product addresses a subset of the uveitis population, specifically patients with associated macular edema who are appropriate for local corticosteroid treatment.
The market has four constraints:
- Uveitic macular edema is materially smaller than the major retinal disease markets.
- Treatment is episodic rather than necessarily chronic or monthly.
- Competing corticosteroid implants have longer market histories.
- Physicians can use lower-cost off-label triamcinolone or systemic therapies.
The market also has growth drivers:
- Greater diagnosis and referral of noninfectious uveitis
- Preference for local treatment in patients with systemic corticosteroid toxicity
- Demand for alternatives to intravitreal implants
- Wider use of office-based retinal procedures
- Potential expansion of suprachoroidal delivery to other retinal diseases
XIPERE’s near-term commercial ceiling is therefore defined more by physician penetration and treatment frequency than by the total ophthalmology market.
What are XIPERE’s sales and financial trajectory?
Bausch + Lomb does not report XIPERE revenue as a standalone line item in its public financial statements. The product is included within broader ophthalmic pharmaceutical or prescription product categories. The company’s filings therefore do not provide verified annual XIPERE sales, gross margin, prescription volume or product-level profitability.[2]
Clearside Biomedical, which developed the suprachoroidal platform, has described its economic interest through licensing, milestone and royalty arrangements with Bausch + Lomb. Clearside’s filings identify XIPERE-related economics, but public disclosures do not provide a complete, consistently reported product-level revenue history that can be used to calculate market share or a precise annual growth rate.[3]
XIPERE financial trajectory
| Period |
Commercial development |
Financial interpretation |
| 2019 |
Bausch + Lomb obtained North American commercial rights under a licensing arrangement with Clearside |
Validated the platform but transferred commercialization risk to a larger ophthalmology company |
| 2021 |
FDA approval |
Established regulatory access to the uveitic macular edema market |
| 2022 |
Commercial launch period |
Initial revenue affected by physician education, reimbursement and procedural adoption |
| 2023 onward |
Expansion through the Bausch + Lomb commercial infrastructure |
Product remained embedded in broader ophthalmic pharmaceutical reporting |
| Long term |
Dependent on adoption and new indications |
Major value creation would require broader use beyond the initial uveitis indication |
The financial model is likely more attractive to Clearside than to Bausch + Lomb on a percentage basis because Clearside can receive royalties without carrying the full commercial infrastructure cost. For Bausch + Lomb, XIPERE contributes to portfolio breadth but is unlikely to be material to consolidated revenue unless the company expands its use into larger retinal indications.
How do reimbursement and procedure economics affect XIPERE demand?
Reimbursement is central to XIPERE adoption because treatment requires both the drug and a specialized administration procedure.
Commercial uptake depends on:
- Coverage of the drug under the relevant medical benefit
- Physician reimbursement for suprachoroidal administration
- Availability of a product-specific billing code or a workable miscellaneous-code pathway
- Patient cost sharing
- Practice economics, including acquisition, inventory and training costs
- Payer preference for lower-cost steroid alternatives
A reimbursement structure that pays adequately for the procedure can support adoption. A drug-only reimbursement approach may leave practices bearing the cost of the injector, staff time and training.
XIPERE’s episodic dosing can improve treatment economics relative to more frequent injections, but the benefit depends on real-world retreatment intervals and the comparative cost of Ozurdex, YUTIQ, Retisert and off-label triamcinolone.
What patent and exclusivity protections cover XIPERE?
XIPERE’s commercial protection is based on formulation, delivery technology, device and method-of-use rights rather than exclusivity for triamcinolone acetonide itself. Triamcinolone is an established corticosteroid with decades of prior clinical use.
FDA exclusivity
The product did not receive the type of new chemical entity exclusivity associated with a novel active ingredient. Any FDA drug exclusivity tied to the approval was therefore more limited than an NCE exclusivity period and did not create a long-term monopoly over triamcinolone products.[1]
Patent protection
The relevant protection categories include:
- Suprachoroidal delivery methods
- The SCS Microinjector
- Injectable suspension characteristics
- Treatment of uveitic macular edema
- Dose and administration parameters
- Manufacturing and device integration
A competitor could face separate barriers for the drug formulation and the delivery system. A copy of the active ingredient alone would not necessarily reproduce the clinical or commercial attributes of XIPERE.
Orange Book status
XIPERE is a small-molecule drug product, not a biologic. Any listed patents, regulatory exclusivity and abbreviated-application certifications should be assessed through the current FDA Orange Book and relevant FDA patent-listing records. Public commercial filings do not establish a complete basis for assigning a definitive generic-entry date.
When could generic or competing entry occur?
Generic entry risk is more complex than for a conventional injectable triamcinolone product because XIPERE combines:
- A known active ingredient
- A specific suspension formulation
- A proprietary administration device
- A specialized route of administration
- A narrow clinical indication
A future applicant could pursue a product that uses the same active ingredient but a different delivery system. That product might avoid some formulation or device claims while creating new clinical and regulatory requirements.
The highest-risk scenario for XIPERE is not necessarily a direct identical generic. It is competitive substitution by:
- Lower-cost intravitreal triamcinolone
- New corticosteroid implants
- Improved long-acting uveitis therapies
- Alternative suprachoroidal products
- Systemic therapies that reduce the need for local treatment
Which companies are competing with or challenging XIPERE?
The competitive field includes:
- Bausch + Lomb, through XIPERE
- AbbVie, through Ozurdex following its acquisition of Allergan
- Alimera Sciences, through YUTIQ and Iluvien-related retinal products
- EyePoint Pharmaceuticals, through sustained-release retinal delivery platforms
- Generic and compounding manufacturers supplying triamcinolone products
- Pharmaceutical companies developing therapies for noninfectious uveitis and retinal inflammation
No public evidence establishes a material Paragraph IV litigation campaign against XIPERE. The more immediate competitive threat is therapeutic substitution rather than a documented direct generic challenge.
What licensing agreements affect XIPERE economics?
Clearside licensed North American commercial rights to Bausch + Lomb. The arrangement gives Bausch + Lomb responsibility for commercial execution and gives Clearside access to milestone and royalty economics tied to XIPERE and related rights.[3]
The licensing structure reduces Clearside’s need to fund a large sales organization. It also limits Clearside’s direct control over pricing, promotion and field-force allocation. Bausch + Lomb gains access to a differentiated retinal delivery technology without developing the platform internally from the beginning.
The value of the agreement depends on the product’s sales trajectory and on whether the suprachoroidal platform generates additional products or indications.
How strong is the XIPERE commercial position?
XIPERE has a differentiated delivery route and FDA approval in a defined clinical niche. Its weaknesses are the small initial indication, procedural complexity, corticosteroid class risks, competition from established implants and limited public evidence of material revenue contribution.
| Factor |
Assessment |
| Regulatory differentiation |
Strong |
| Active-ingredient differentiation |
Weak, because triamcinolone is long established |
| Delivery-system differentiation |
Stronger than the molecule-level position |
| Market size |
Niche |
| Physician adoption barrier |
Moderate to high |
| Reimbursement sensitivity |
High |
| Generic substitution risk |
Moderate, with route and device complexity limiting direct substitution |
| Revenue visibility |
Low because Bausch + Lomb does not separately report sales |
| Expansion potential |
Material if additional retinal indications are approved |
| Near-term commercial outlook |
Gradual adoption rather than rapid blockbuster growth |
Key Takeaways
- XIPERE is an FDA-approved suprachoroidal triamcinolone product for macular edema associated with uveitis.
- Its commercial advantage is the delivery route, not the active ingredient.
- The initial market is narrow compared with diabetic macular edema, age-related macular degeneration and retinal vein occlusion.
- Ozurdex, YUTIQ, Retisert, off-label intravitreal triamcinolone and systemic therapies are the principal alternatives.
- Bausch + Lomb does not disclose standalone XIPERE sales, preventing precise revenue or market-share calculations.
- Clearside benefits from licensing and royalty economics but has limited direct control over commercial execution.
- The main near-term risks are physician adoption, reimbursement, procedural complexity and low-cost therapeutic substitution.
- Significant upside depends on new indications for suprachoroidal delivery or broader use in retinal inflammation.
- XIPERE does not have biologic exclusivity, and triamcinolone itself is not a novel active ingredient.
- The product is more likely to develop into a specialized ophthalmic franchise than a large standalone pharmaceutical asset.
FAQs
Is XIPERE a biologic or a generic drug?
XIPERE is a small-molecule corticosteroid drug product containing triamcinolone acetonide. It is not a biologic and is not subject to biosimilar competition.
Who commercializes XIPERE?
Bausch + Lomb commercializes XIPERE in the licensed North American market. Clearside Biomedical developed the suprachoroidal delivery platform and receives contractual economic benefits under its licensing arrangement.
Is XIPERE used for diabetic macular edema?
The FDA-approved indication is macular edema associated with uveitis. Use in diabetic macular edema would require separate regulatory support and is not established by the approved label.
Does XIPERE replace Ozurdex?
No. XIPERE and Ozurdex are competing corticosteroid options with different delivery systems. Ozurdex has broader retinal use and longer market experience, while XIPERE offers a suprachoroidal alternative.
What is the biggest financial risk for XIPERE?
The primary financial risk is failure to achieve sufficient physician and payer adoption in a narrow indication. Without expansion into larger retinal markets, product revenue is likely to remain a relatively small component of Bausch + Lomb’s ophthalmology portfolio.
References
- U.S. Food and Drug Administration. (2021). XIPERE (triamcinolone acetonide injectable suspension) prescribing information.
- Bausch + Lomb Corporation. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Clearside Biomedical, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
